-
The rates of septicemia in older adults with prostate cancer treated with abiraterone or enzalutamide: A population-based study.
06 May 2024 08:55 GMT
Prostate cancer (PCa) is the most common … abiraterone is usually prescribed with prednisone, we sought to compare the …
-
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer.
30 Apr 2024 08:40 GMT
… classifiers for metastatic castration-resistant prostate cancers (mCRPC).
In a modular, … 8 weeks of abiraterone acetate, prednisone and apalutamide (AAPA; Module 1 … metastatic biopsies. The aggressive variant prostate cancer molecular profile (defects in ≥2 …
-
Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial.
09 Apr 2024 10:35 GMT
… first-line metastatic castration-resistant prostate cancer (mCRPC) setting, irrespective of … abiraterone (1000 mg od) plus prednisone/prednisolone (5 mg … treatment for metastatic castration-resistant prostate cancer, olaparib combined with abiraterone …
-
Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer.
08 Apr 2024 19:49 GMT
… men with newly diagnosed oligometastatic prostate cancer (OMPCa). Men with ≤ 5 sites … 12/12 (100%), abiraterone + prednisone 6/12 (50%)], adjuvant …
-
A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer.
26 Mar 2024 08:22 GMT
ModraDoc006, an oral formulation of docetaxel, is co-administered with the cytochrome P450-3A4 and P-glycoprotein inhibitor, ritonavir (r): ModraDoc006/r. The preliminary efficacy and safety of oral ModraDoc006/r was evaluated in a global …
-
Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial.
19 Mar 2024 08:00 GMT
… men with metastatic hormone-sensitive prostate cancer treated with intermittent androgen … AAT; leuprolide, abiraterone acetate plus prednisone, and apalutamide) and metastasis-directed … men with recurrence of metastatic prostate cancer. We found that half …
-
Targeted Ultrasound Nanobubbles Therapy for Prostate Cancer via Immuno-Sonodynamic Effect
18 Mar 2024 13:18 GMT
… plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. … hormone-sensitive metastatic prostate cancer: evidences and uncertainties … of the prostate cancer microenvironment influences the … imaging of prostate cancer with PSMA-targeted …
-
What to know about recurrent prostate cancer
18 Mar 2024 12:48 GMT
… treatments for recurrent prostate cancer, including surgery, radiotherapy … orchiectomy can cause most prostate cancers to stop growing. … levels to treat prostate cancer. Now, doctors … therapy — abiraterone/prednisone, enzalutamide, or apalutamide — …
-
AZ/Merck’s Lynparza approved by SMC to treat advanced prostate cancer in Scotland
18 Mar 2024 10:51 GMT
… to 20% of prostate cancer cases are classified … prednisone or prednisolone to treat adult patients with metastatic castration-resistant prostate cancer … to 20% of prostate cancer cases are classified as … patients with advanced prostate cancer can now access …
-
Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance).
06 Mar 2024 11:06 GMT
… with metastatic castration-resistant prostate cancer received docetaxel and prednisone ± bevacizumab. Patients were …